

BRAND NAME	ACTIVE INGREDIENT / TECHNOLOGY	INDICATION RANGE <sup>1</sup>	SALES <sup>2</sup> 2021 IN € MILLION
 <b>Qutenza</b> <small>capsaicin 8% patch</small>	Capsaicin	<b>EU indication:</b> Treatment of peripheral neuropathic pain in adults either alone or in combination with other medicinal products for the treatment of pain.  <b>US indication:</b> Treatment of neuropathic pain associated with postherpetic neuralgia (PHN) and for neuropathic pain associated with diabetic peripheral neuropathy (DPN) of the feet in adults.	42.8
	Fixed-dose combination of Esomeprazole and Naproxen	In adults for the symptomatic treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis, in patients who are at risk for developing non-steroidal anti-inflammatory drug (NSAID)-associated gastric and/or duodenal ulcers and where treatment with lower doses of naproxen or of other NSAIDs is not considered sufficient.	46.4
	Lidocaine	<b>EU and Peru indication:</b> Symptomatic relief of neuropathic pain associated with previous herpes zoster infection (postherpetic neuralgia, PHN) in adults.  <b>Latin America indication:</b> Symptomatic relief of neuropathic pain associated with previous herpes zoster infection (postherpetic neuralgia, PHN) in adults. Symptomatic relief of Localised Neuropathic Pain in adults.	137.3
 <b>Zomig</b> <small>ZOLMITRIPTAN</small>  <b>AscoTop</b> <sup>®</sup>	Zolmitriptan	<b>Oral formulations:</b> In adults aged 18 years and older for acute treatment of migraine headache with or without aura.  <b>Nasal spray:</b> In adults and adolescents aged 12 years and older for the acute treatment of migraine headache with or without aura, and in adults for the treatment of cluster headache.	62.7
 <b>Nexium</b> <small>esomeprazole</small>	Esomeprazole	<b>20 mg; 40 mg gastro-resistant tablets:</b> <b>Indicated in adolescents from the age of 12 years and in adults for:</b>  Gastroesophageal reflux disease (GERD) <ul style="list-style-type: none"> <li>treatment of erosive reflux esophagitis</li> <li>long-term management of patients with healed esophagitis to prevent relapse</li> <li>symptomatic treatment of GERD</li> </ul> <b>Indicated in adults for:</b> In combination with appropriate antibacterial therapeutic regimens for the eradication of <i>Helicobacter pylori</i> and: <ul style="list-style-type: none"> <li>healing of <i>Helicobacter pylori</i> associated duodenal ulcer and</li> <li>prevention of relapse of peptic ulcers in patients with <i>Helicobacter pylori</i>-associated ulcers</li> </ul> <b>Patients requiring continued NSAID therapy:</b> <ul style="list-style-type: none"> <li>healing of gastric ulcers associated with NSAID therapy</li> <li>prevention of gastric and duodenal ulcers associated with NSAID therapy, in patients at risk</li> </ul> <b>Prolonged treatment after intravenous-induced prevention of rebleeding of peptic ulcers. Treatment of Zollinger Ellison Syndrome.</b>  <b>Indicated in adolescents from the age of 12 years:</b> In combination with antibiotics in treatment of duodenal ulcer caused by <i>Helicobacter pylori</i> . Nexium™ is also available in other dosage forms with slightly varying indications. <sup>3</sup>	187.0
 <b>CRESTOR</b> <sup>®</sup>	Rosuvastatin	<b>Treatment of hypercholesterolaemia</b> Adults, adolescents and children aged 6 years or older with primary hypercholesterolaemia (type IIa including heterozygous familial hypercholesterolaemia) or mixed dyslipidaemia (type IIb) as an adjunct to diet when response to diet and other non-pharmacological treatments (e.g. exercise, weight reduction) is inadequate. Adults, adolescents and children aged 6 years or older with homozygous familial hypercholesterolaemia as an adjunct to diet and other lipid lowering treatments (e.g. LDL apheresis) or if such treatments are not appropriate.  <b>Prevention of cardiovascular events</b> Prevention of major cardiovascular events in patients who are estimated to have a high risk for a first cardiovascular event, as an adjunct to correction of other risk factors.	72.2 <sup>4</sup>
 <b>PALEXIA</b> <sup>®</sup>	Tapentadol	<b>Film-coated IR tablet:</b> Relief of moderate to severe acute pain in adults which can be adequately managed only with opioid analgesics.  <b>Oral solution:</b> Relief of moderate to severe acute pain in children <sup>5</sup> from 2 years of age and in adults, which can be adequately managed only with opioid analgesics.  <b>Prolonged-release tablet:</b> Management of severe chronic pain in adults which can be adequately managed only with opioid analgesics.	<b>Palexia™</b> <b>315.5</b>  +  <b>Partner sales of Nucynta™ in the US: \$173.2 mn</b>
	Tramadol	<b>EU and LATAM indication:</b> Treatment of moderate to severe pain.	85.9
	Fixed-dose combination of Tramadol and Paracetamol	Symptomatic treatment of moderate to severe pain; use should be restricted to patients whose moderate to severe pain is considered to require a combination of tramadol and paracetamol.	60.1
 <b>NORSPAN</b> <sup>®</sup> <small>DAS 7-TAGE-SCHMERZPLASTER</small>  <b>Transtec</b> <sup>®</sup>	Buprenorphine	Treatment of moderate to severe cancer pain and severe pain which does not respond to non-opioid analgesics. Transtec is not suitable for the treatment of acute pain.	47.8

<sup>1</sup> Status: April 2022. Please note that indications and formulations may vary from country to country. Please refer to the respective local product information or Summary of Product Characteristics (SmPC)

<sup>2</sup> without license and milestone income

<sup>3</sup> see SmPC for 'Nexium™ 10 mg gastro-resistant granules for oral suspension, sachet' and for 'Nexium™ 40 mg Powder for solution for injection/infusion'

<sup>4</sup> profit transfer following the acquisition of Crestor™ in February 2021

<sup>5</sup> in children restricted to hospital use where appropriate equipment to enable respiratory support is available and for a maximum treatment duration of 3 days